New Hope for Muscular Dystrophy: Advances in Diagnostics and Treatment
Two common types of muscular dystrophy, Duchenne (DMD) and Becker (BMD), affect males worldwide. Recent advancements in diagnostics and treatment come from leading institutions like the National Institutes of Health, University of Oxford, UMC Utrecht, and Telethon Institute.
DMD symptoms manifest in toddlers aged 2 to 3, while BMD symptoms can appear anytime from 5 years to 60. BMD progresses slower and less predictably than DMD. Historically, life expectancy was longer in BMD, but DMD treatments have improved this.
Both conditions are more common in males due to their single X chromosome. BMD is less common and severe than DMD. DMD results from a lack of functional dystrophin protein, while BMD produces a partially functional version. Almost all DMD patients need mobility aids by 13, while most BMD patients can walk unassisted into their 40s. Around 400 to 600 boys are born with these conditions in the US each year.
Muscular dystrophies cause progressive muscle tissue breakdown. DMD and BMD, the most common types, affect males predominantly. Recent research from leading institutions aims to improve diagnostics and treatment, enhancing life expectancy and quality of life for those affected.
Read also:
- Capella Nursing Students Gear Up for Crucial FPX 4050 Assessments
- Comprehensive Overview of Addressing Traumatic Brain Injuries (TBIs)
- Enhanced Health Services Provisioned by San Diego Academic Health Partnership Continues During COVID-19 and Beyond
- Vaccination drive targeting infants under 6 months old against bronchiolitis in the region of Andalucia
